Antiviral humanized and human monoclonal antibodies


Cite item

Full Text

Abstract

The paper considers the characteristics of monoclonal antibodies, methods for their experimental preparation, problems of their production, and possibilities of their use for the emergency prevention of viral infections and for the treatment of chronic diseases caused by human immunodeficiency virus, hepatitis B and C viruses, and herpes viruses. The future of experimentally produced or clinically trialed monoclonal antibodies is mainly determined by commercial considerations. It is possible that simplification of industrial production technologies and a reduction in the cost of evidence-based methods for evaluation of clinical effectiveness will allow monoclonal antibodies to be extensively used for the prevention and treatment of viral infections.

References

  1. Лашкевич В. А. Использование моноклональных антител в вирусологии // Вопр. вирусол. - 1983. - № 6. - С. 648- 654.
  2. Медуницын Н. В. Вакцинология. - М., 2004.
  3. Никифоров А. К., Волох О. А., Лобовикова О. Ф. и др. Препарат антирабического иммуноглобулина на основе F(ab)2-фрагментов // Журн. микробиол. - 2007. - № 1. - С. 72- 74.
  4. Bakker A. B., Marissen W. E., Kramer R. A. et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants // J. Virol. - 2005. - Vol. 79. - P. 9062-9068.
  5. Bakker A. B., Python C., Kissling C. J. et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity // Vaccine. - 2008. - Vol. 26. - P. 5922-5927.
  6. Beerli R. R., Bauer M., Schmitz N. et al. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein // Virol. J. - 2009. - Vol. 6. - P. 224.
  7. Bossart K. N., Zhu Z., Middleton D. et al. A neutralizing human monoclonal antibody protects against lethal disease in new ferret model of acute Nipah virus infection // PLoS Pathog. - 2008. - Vol. 5. - e1000642.
  8. Bourhy H.,, Dacheux L., Ribadeau-Dumas F. The use of passive rabies immunotherapy: from the past to the future // Biol. Aujourdhui. - 2010. - Vol. 204. - P. 71-80.
  9. Casali P., Inghiremi G., Nakamura M. et al. Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV // Science. - 1986. - Vol. 234. - P. 476-479.
  10. Chen Z., Earl P., Americo J. et al. Chimpanzee/Human mAbs to vaccinia virus B5 prote3in neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus // Proc. Natl. Acad. Sci. USA. - 2006. - Vol. 103. - P. 1822-1887.
  11. Chen Z., Earl P., Americo J. et al. Characterization of chimpanzee/Human monoclonbal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model // J. Virol. - 2007. - Vol. 81. - P. 8989-8995.
  12. Dietzschold B., Gore M., Casali P. et al. Biological characterization of human monoclonal antibodies to rabies virus //J. Virol. - 1990. - Vol. 64. - P. 3087-3090.
  13. Enssle K., Kurrle R., Kohler R. et al. A rabies-specific human monoclonal antibody that protects mice against lethal rabies // Hybridoma. - 1991. - Vol. 10. - P. 547-556.
  14. Funaro A., Gribaudo G., Luganini A. et al. Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells // BMC Biotechnology. - 2008. - Vol. 8. - P. 85.
  15. Good Manufacturing Practices for Biological Products // WHO Techn. Rep. Ser. - 1992. - N 822. - P. 20-30.
  16. Guidelines for National Authorities on Quality Assurance for Biological Products // WHO Techn. Rep. Ser. - 1992. - N 822. - P. 31-46.
  17. Guidelines for Assuring the Quality of Monoclonal Antibodies for Use in Humans // WHO Techn. Rep. Ser. - 1992. - N 822. - P. 47-68.
  18. Human trials on for new antibody to neutralize rabies virus // Indian Express Com. - 2010. - Nov. 14.
  19. Karpas A., Dremucheva A., Czepulkovski B. H. A human myeloma cell line suitable for the generation of human monoclonal antibodies // Proc. Natl. Acad. Sci. USA. - 2001. - Vol. 98. - P. 1799-1804.
  20. Klasse P. J., Sasttentau Q. J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses // J. Gen. Virol. - 2002. - Vol. 83. - P. 2091-2108.
  21. Kohler G., Milstein C. Continuous cultures of fused cells, secreting antibody of predicted specificity // Nature. - 1975. - Vol. 256. - P. 495-497.
  22. Kramer R. A., Marissen W. E., Goldsmith J. et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries // Eur. J. Immunol. - 2005. - Vol. 35. - P. 2131-2145.
  23. Lundkvist A., Horling J., Atlin L. et al. Neutralizing human monoclonal antibodies against Puumala virus, causative agent of nefropathia epidemica: novel method using antigen-coated magnetic beads for specific B cell isolation // J. Gen. Virol. - 1993. - Vol. 74. - P. 1303-1310.
  24. Marasco W. A., Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics // Nat. Biotechnol. - 2007. - Vol. 25. - P. 1421-1434.
  25. Marissen W. E., Kramer R. A., Rice A. et al. Novel rabies virus neutralizing epitope recognized by human monoclonal antibody: fin mapping and escape mutant analysis // J. Virol. - 2005. - Vol. 79. - P. 4672-4678.
  26. Matsumoto T., Yamada K., Noguchi K. et al. Isolation and characterization of novel human monoclonal antibodies possessing neutralizing ability against rabies virus // Microbiol. Immunol. - 2010. - Vol. 54. - P. 673-683.
  27. McCafferty J., Griffiths A. D., Winter G., Chiswell D. J. Phage antibodies: filamentous phage displaying antibody variable domains // Nature. - 1990. - Vol. 348. - P. 552-554.
  28. Michaud H., Gomard M., Gros L. et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy // PLoS Pathog. - 2010. - Vol. 6. - e1000948.
  29. Ni J. New technologies for the generation of human monoclonal antibody // Trends in Bio/Pharmacol. Industry. - 2009. - Vol. 5. - P. 3-12.
  30. Prosniak M., Faber M., Hanlon C. A. et al. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for post-exposure prophylaxis // Vaccine. - 2003. - Vol. 18. - P. 53-56.
  31. Rabies Vaccines. WHO Position Paper // Wkly Epidemiol. Rec. - 2007. - Vol. 82. - P. 425-436.
  32. Schmaljohn C., Cui Y., Kerby S. et al. Pruduction and characterization of human monoclonal antibody Fab fragments to vaccinia virus from phage-display combinatorial library // Virology. - 1999. - Vol. 258. - P. 189-200.
  33. Sloan S. E., Hanlon C., Weldon W. et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates // Vaccine. - 2007. - Vol. 25. - P. 2800-2810.
  34. Smith G. P. Filamentous fusion phage; novel expression vectors that display cloned antigens on the virus surface // Science. - 1985. - Vol. 228. - P. 1315-1317.
  35. Smith G. P., Petrenko V. A. Phage display // Chem. Rev. - 1997. - Vol. 97. - P. 391-410.
  36. Wiktor T. J., Koprowski H. Monoclonal antibodies against rabies virus produced by somatic cell hybridization // Proc. Natl. Acad. Sci. USA. - 1978. - Vol. 75. - P. 3938-3942.
  37. Xiao Y., Isaacs S. N. Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections // Viruses. - 2010. - Vol. 2. - P. 2381-2403.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Lashkevich V.A., Lashkevich V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies